You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLabetalol
Accession NumberDB00598  (APRD01062)
TypeSmall Molecule
GroupsApproved
Description

Blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive. [PubChem]

Structure
Thumb
Synonyms
3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
Labetalol
Labetalolum
Labetolol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Labetalol Hydrochloridetablet300 mg/1oralCounty Line Pharmaceuticals LLC2014-12-01Not applicableUs
Labetalol Hydrochloridetablet200 mg/1oralCounty Line Pharmaceuticals LLC2014-12-01Not applicableUs
Labetalol Hydrochloridetablet100 mg/1oralCounty Line Pharmaceuticals LLC2014-12-01Not applicableUs
Labetalol Hydrochloride Injection USPsolution5 mgintravenousHospira Healthcare Corporation2015-06-02Not applicableCanada
Labetalol Hydrochloride Injection USPliquid5 mgintravenousSandoz Canada Incorporated1998-03-17Not applicableCanada
Labetalol Hydrochloride Injection, USPsolution5 mgintravenousMylan Pharmaceuticals Ulc2012-08-29Not applicableCanada
Labetolol Hydrochloride Injection USPsolution5 mgintravenousSterimax IncNot applicableNot applicableCanada
Mylan-labetalol Hydrochloride Injection, USPsolution5 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Trandatetablet100 mg/1oralPrometheus Laboratories Inc.1984-05-31Not applicableUs
Trandatetablet200 mgoralPaladin Labs Inc1997-04-01Not applicableCanada
Trandatetablet100 mgoralPaladin Labs Inc1996-07-30Not applicableCanada
Trandatetablet300 mg/1oralPrometheus Laboratories Inc.1984-05-31Not applicableUs
Trandatetablet200 mg/1oralPrometheus Laboratories Inc.1984-05-31Not applicableUs
Trandate 5mg/mlliquid5 mgintravenousShire Biochem Inc1996-08-232003-10-16Canada
Trandate Inj 5mg/mlliquid5 mgintravenousGlaxo Canada Inc1986-12-311996-09-10Canada
Trandate Tab 100mgtablet100 mgoralGlaxo Canada Inc1984-12-311996-09-10Canada
Trandate Tab 200mgtablet200 mgoralGlaxo Canada Inc1984-12-311998-07-31Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-labetalol Tabletstablet200 mgoralApotex Inc2001-06-01Not applicableCanada
Apo-labetalol Tabletstablet100 mgoralApotex Inc2001-03-16Not applicableCanada
Labetaloltablet, film coated300 mg/1oralSun Pharmaceutical Industries, Inc.1999-07-29Not applicableUs
Labetalolinjection5 mg/mLintravenousSagent Pharmaceuticals2010-02-17Not applicableUs
Labetaloltablet, film coated200 mg/1oralSun Pharmaceutical Industries, Inc.1999-07-29Not applicableUs
Labetaloltablet, film coated100 mg/1oralSun Pharmaceutical Industries, Inc.1999-07-29Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralPar Pharmaceutical Inc.2012-07-24Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralREMEDYREPACK INC.2013-10-29Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralREMEDYREPACK INC.2015-10-20Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralPar Pharmaceutical Inc.2012-07-24Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralCardinal Health2011-05-06Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralMylan Institutional Inc.2000-01-15Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralCardinal Health2011-05-06Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralMylan Institutional Inc.2000-01-15Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralEon Labs, Inc.1998-08-04Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralEon Labs, Inc.1998-08-04Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralCardinal Health1998-08-04Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralAmerican Health Packaging2015-06-01Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralEon Labs, Inc.1998-08-04Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2006-11-15Not applicableUs
Labetalol HCltablet, film coated200 mg/1oralAmerican Health Packaging2015-06-01Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralAmerican Health Packaging2015-06-01Not applicableUs
Labetalol HCltablet, film coated100 mg/1oralREMEDYREPACK INC.2016-02-23Not applicableUs
Labetalol HCltablet, film coated300 mg/1oralPar Pharmaceutical Inc.2012-07-24Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralGolden State Medical Supply, Inc.2013-04-16Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralAmerican Health Packaging2011-03-08Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2010-11-30Not applicableUs
Labetalol Hydrochloridetablet200 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Labetalol Hydrochloridetablet300 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralWatson Laboratories, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralGolden State Medical Supply, Inc.2013-04-16Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralIVAX Pharmaceuticals, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet200 mg/1oralCardinal Health2009-06-10Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousGland Pharma Limited2012-04-19Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC1998-08-03Not applicableUs
Labetalol Hydrochloridetablet100 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousHospira, Inc.1999-11-29Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2015-08-13Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-01Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousHospira, Inc.1999-11-29Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralSt Marys Medical Park Pharmacy2014-01-30Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralRebel Distributors Corp1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-01Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousCardinal Health1999-11-29Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralSt Marys Medical Park Pharmacy2014-01-30Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralUnit Dose Services1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralRebel Distributors Corp1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-01Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralCardinal Health2011-01-01Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousMylan Institutional LLC2012-06-29Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralAmerican Health Packaging2011-03-082015-12-01Us
Labetalol Hydrochloridetablet, film coated100 mg/1oralUnit Dose Services1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralRebel Distributors Corp1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-14Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralCardinal Health2011-01-01Not applicableUs
Labetalol Hydrochloridetablet, film coated100 mg/1oralPhysicians Total Care, Inc.2004-05-06Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralMc Kesson Contract Packaging2012-03-21Not applicableUs
Labetalol Hydrochloridetablet200 mg/1oralREMEDYREPACK INC.2011-09-27Not applicableUs
Labetalol Hydrochlorideinjection, solution5 mg/mLintravenousAkorn, Inc.2004-09-01Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralWatson Laboratories, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralIVAX Pharmaceuticals, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet100 mg/1oralCardinal Health2009-06-10Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralPhysicians Total Care, Inc.2004-08-25Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralbryant ranch prepack1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralDispensing Solutions, Inc.2011-01-01Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralCardinal Health2011-03-08Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralPhysicians Total Care, Inc.2003-08-19Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralbryant ranch prepack1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralGolden State Medical Supply, Inc.2013-04-16Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralAmerican Health Packaging2011-03-08Not applicableUs
Labetalol Hydrochloridetablet300 mg/1oralREMEDYREPACK INC.2011-06-20Not applicableUs
Labetalol Hydrochloridetablet, film coated300 mg/1oralSTAT Rx USA LLC1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralWatson Laboratories, Inc.1998-08-03Not applicableUs
Labetalol Hydrochloridetablet, film coated200 mg/1oralIVAX Pharmaceuticals, Inc.1998-08-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Labetalol HClinjection, solution5 mg/mLintravenousCantrell Drug Company2012-02-23Not applicableUs
International Brands
NameCompany
AlbetolLeiras
LatolStandard
NormadateGlaxoSmithKline
NormodyneSchering
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Labetalol Hydrochloride
Thumb
  • InChI Key: WQVZLXWQESQGIF-UHFFFAOYNA-N
  • Monoisotopic Mass: 364.155370383
  • Average Mass: 364.866
DBSALT000320
Categories
UNIIR5H8897N95
CAS number36894-69-6
WeightAverage: 328.4055
Monoisotopic: 328.178692644
Chemical FormulaC19H24N2O3
InChI KeyInChIKey=SGUAFYQXFOLMHL-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
IUPAC Name
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
SMILES
CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylamides
Alternative Parents
Substituents
  • Salicylamide
  • Phenylpropylamine
  • Benzamide
  • Benzoyl
  • Aralkylamine
  • Phenol
  • Vinylogous acid
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Carboxamide group
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of hypertension (alone or in combination with other classes of antihypertensive agents), as well as chronic stable angina pectoris and sympathetic overactivity syndrome associated with severe tetanus. Labetalol is used parenterally for immediate reduction in blood pressure in severe hypertension or in hypertensive crises when considered an emergency, for the control of blood pressure in patients with pheochromocytoma and pregnant women with preeclampsia, and to produce controlled hypotension during anesthesia to reduce bleeding resulting from surgical procedures.
PharmacodynamicsLabetalol is an selective alpha-1 and non-selective beta adrenergic blocker used to treat high blood pressure. It works by blocking these adrenergic receptors, which slows sinus heart rate, decreases peripheral vascular resistance, and decreases cardiac output. Labetalol has two asymmetric centers and therefore, exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,R' stereoisomer, makes up 25% of racemic labetalol.
Mechanism of actionLabetalol HCl combines both selective, competitive, alpha-1-adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta- blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively. The principal physiologic action of labetalol is to competitively block adrenergic stimulation of β-receptors within the myocardium (β1-receptors) and within bronchial and vascular smooth muscle (β2-receptors), and α1-receptors within vascular smooth muscle. This causes a decrease in systemic arterial blood pressure and systemic vascular resistance without a substantial reduction in resting heart rate, cardiac output, or stroke volume, apparently because of its combined α- and β-adrenergic blocking activity.
Related Articles
AbsorptionCompletely absorbed (100%) from the gastrointestinal tract with peak plasma levels occurring 1 to 2 hours after oral administration. The absolute bioavailability of labetalol is increased when administered with food.
Volume of distributionNot Available
Protein binding50%
Metabolism

Primarily hepatic, undergoes significant first pass metabolism

Route of eliminationThese metabolites are present in plasma and are excreted in the urine, and via the bile, into the feces.
Half life6-8 hours
ClearanceNot Available
ToxicityLD50 = 66 mg/kg (Rat, IV). Side effects or adverse reactions include dizziness when standing up, very low blood pressure, severely slow heartbeat, weakness, diminished sexual function, fatigue
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Labetalol Action PathwayDrug actionSMP00368
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier-0.8313
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7073
P-glycoprotein inhibitor INon-inhibitor0.8908
P-glycoprotein inhibitor IINon-inhibitor0.9269
Renal organic cation transporterNon-inhibitor0.8457
CYP450 2C9 substrateNon-substrate0.7448
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6202
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.8256
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8383
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9189
BiodegradationNot ready biodegradable0.945
Rat acute toxicity2.1174 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9501
hERG inhibition (predictor II)Non-inhibitor0.7398
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apothecon inc div bristol myers squibb
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Taylor pharmaceuticals
  • Sagent strides llc
  • Schering corp sub schering plough corp
  • Prometheus laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous5 mg/mL
Injection, solutionintravenous5 mg/mL
Tabletoral100 mg/1
Tabletoral200 mg/1
Tabletoral300 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral200 mg/1
Tablet, film coatedoral300 mg/1
Liquidintravenous5 mg
Solutionintravenous5 mg
Tabletoral100 mg
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Labetalol Hydrochloride 5 mg/ml1.36USD ml
Trandate 300 mg tablet1.28USD tablet
Trandate 5 mg/ml vial1.25USD ml
Trandate 200 mg tablet1.08USD tablet
Labetalol hcl 300 mg tablet1.02USD tablet
Normodyne 200 mg tablet1.0USD tablet
Labetalol hcl 200 mg tablet0.76USD tablet
Trandate 100 mg tablet0.68USD tablet
Labetalol hcl 100 mg tablet0.53USD tablet
Trandate 200 mg Tablet0.47USD tablet
Trandate 100 mg Tablet0.27USD tablet
Labetalol hcl 5 mg/ml vial0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point188 °CU.S. Patent 4,012,444.
water solubility117 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP3.09HANSCH,C ET AL. (1995)
Caco2 permeability-5.03ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00578 mg/mLALOGPS
logP1.73ALOGPS
logP1.89ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)8.05ChemAxon
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area95.58 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity94.72 m3·mol-1ChemAxon
Polarizability36.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-03dl-7900000000-e18d52bcb93357c4a7e2View in MoNA
References
Synthesis Reference

U.S. Patent 4,012,444.

General ReferencesNot Available
External Links
ATC CodesC07AG01C07BG01C07CG01
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (401 KB)
MSDSDownload (53.7 KB)
Interactions
Drug Interactions
Drug
AcepromazineAcepromazine may increase the hypotensive activities of Labetalol.
AcetaminophenThe risk or severity of adverse effects can be increased when Labetalol is combined with Acetaminophen.
AcetylcholineThe risk or severity of adverse effects can be increased when Labetalol is combined with Acetylcholine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Labetalol is combined with Acetylsalicylic acid.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.
AlfuzosinLabetalol may increase the orthostatic hypotensive activities of Alfuzosin.
AmifostineLabetalol may increase the hypotensive activities of Amifostine.
AminophyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Labetalol.
AmphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Amphetamine.
ArformoterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Arformoterol.
ArmodafinilThe risk or severity of adverse effects can be increased when Labetalol is combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Labetalol is combined with Articaine.
AtomoxetineAtomoxetine may increase the hypertensive activities of Labetalol.
BenzphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Benzphetamine.
BretyliumBretylium may increase the bradycardic activities of Labetalol.
BrimonidineBrimonidine may increase the antihypertensive activities of Labetalol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Labetalol.
ButabarbitalThe serum concentration of Labetalol can be decreased when it is combined with Butabarbital.
ButalbitalThe risk or severity of adverse effects can be increased when Labetalol is combined with Butalbital.
ButethalThe serum concentration of Labetalol can be decreased when it is combined with Butethal.
CabergolineLabetalol may increase the vasoconstricting activities of Cabergoline.
CaffeineThe risk or severity of adverse effects can be increased when Labetalol is combined with Caffeine.
CarbacholThe risk or severity of adverse effects can be increased when Labetalol is combined with Carbachol.
CeritinibLabetalol may increase the bradycardic activities of Ceritinib.
ChloroquineThe metabolism of Labetalol can be decreased when combined with Chloroquine.
ChlorpropamideLabetalol may increase the hypoglycemic activities of Chlorpropamide.
CocaineThe risk or severity of adverse effects can be increased when Labetalol is combined with Cocaine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Labetalol is combined with Dexmethylphenidate.
DextroamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dextroamphetamine.
DiazoxideDiazoxide may increase the hypotensive activities of Labetalol.
DiethylpropionThe risk or severity of adverse effects can be increased when Labetalol is combined with Diethylpropion.
DigoxinLabetalol may increase the bradycardic activities of Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dihydrocodeine.
DipivefrinThe risk or severity of adverse effects can be increased when Labetalol is combined with Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Labetalol.
DisopyramideDisopyramide may increase the bradycardic activities of Labetalol.
DobutamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dobutamine.
DopamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dopamine.
DoxapramThe risk or severity of adverse effects can be increased when Labetalol is combined with Doxapram.
DronabinolDronabinol may increase the tachycardic activities of Labetalol.
DronedaroneDronedarone may increase the bradycardic activities of Labetalol.
DuloxetineLabetalol may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dyphylline.
EphedrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Ephedrine.
EpinephrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Epinephrine.
EsmololEsmolol may increase the bradycardic activities of Labetalol.
FenoterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Fenoterol.
FingolimodLabetalol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Labetalol.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Labetalol is combined with Fluticasone Propionate.
FormoterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Formoterol.
HeptabarbitalThe serum concentration of Labetalol can be decreased when it is combined with Heptabarbital.
HexobarbitalThe serum concentration of Labetalol can be decreased when it is combined with Hexobarbital.
IndacaterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Indacaterol.
InfliximabInfliximab may decrease the antihypertensive activities of Labetalol.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Labetalol.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Labetalol is combined with Ipratropium bromide.
IsomethepteneThe risk or severity of adverse effects can be increased when Labetalol is combined with Isometheptene.
IvabradineLabetalol may increase the bradycardic activities of Ivabradine.
LacosamideLabetalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LevodopaLabetalol may increase the orthostatic hypotensive activities of Levodopa.
LevonordefrinThe risk or severity of adverse effects can be increased when Labetalol is combined with Levonordefrin.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Labetalol.
LinezolidLinezolid may increase the hypertensive activities of Labetalol.
LisdexamfetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Lisdexamfetamine.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Labetalol.
MethacholineThe risk or severity of adverse effects can be increased when Labetalol is combined with Methacholine.
MethamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Methamphetamine.
MethohexitalThe serum concentration of Labetalol can be decreased when it is combined with Methohexital.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Labetalol.
MidodrineLabetalol may increase the bradycardic activities of Midodrine.
ModafinilThe risk or severity of adverse effects can be increased when Labetalol is combined with Modafinil.
MolsidomineMolsidomine may increase the hypotensive activities of Labetalol.
MoxonidineMoxonidine may increase the hypotensive activities of Labetalol.
NabiloneNabilone may increase the tachycardic activities of Labetalol.
NaphazolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Naphazoline.
NicorandilNicorandil may increase the hypotensive activities of Labetalol.
NifedipineNifedipine may increase the hypotensive activities of Labetalol.
NorepinephrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Norepinephrine.
ObinutuzumabLabetalol may increase the hypotensive activities of Obinutuzumab.
OctreotideOctreotide may increase the bradycardic activities of Labetalol.
OlodaterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Olodaterol.
OrciprenalineLabetalol may decrease the activities of Orciprenaline.
OxymetazolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Oxymetazoline.
PentobarbitalThe serum concentration of Labetalol can be decreased when it is combined with Pentobarbital.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Labetalol.
PhendimetrazineThe risk or severity of adverse effects can be increased when Labetalol is combined with Phendimetrazine.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Labetalol.
PheniramineThe risk or severity of adverse effects can be increased when Labetalol is combined with Pheniramine.
PhentermineThe risk or severity of adverse effects can be increased when Labetalol is combined with Phentermine.
PhenylephrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Phenylephrine.
PirbuterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Pirbuterol.
PrazosinLabetalol may increase the orthostatic hypotensive activities of Prazosin.
PrimidoneThe serum concentration of Labetalol can be decreased when it is combined with Primidone.
PropafenoneThe serum concentration of Labetalol can be increased when it is combined with Propafenone.
PropylhexedrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Propylhexedrine.
PseudoephedrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Pseudoephedrine.
QuinineQuinine may increase the hypotensive activities of Labetalol.
RacepinephrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Racepinephrine.
RegorafenibRegorafenib may increase the bradycardic activities of Labetalol.
ReserpineReserpine may increase the hypotensive activities of Labetalol.
RisperidoneLabetalol may increase the hypotensive activities of Risperidone.
RituximabLabetalol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Labetalol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Labetalol.
SalbutamolThe risk or severity of adverse effects can be increased when Labetalol is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Salmeterol.
SecobarbitalThe serum concentration of Labetalol can be decreased when it is combined with Secobarbital.
SufentanilSufentanil may increase the bradycardic activities of Labetalol.
TacrineTacrine may increase the bradycardic activities of Labetalol.
TadalafilTadalafil may increase the antihypertensive activities of Labetalol.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Labetalol.
TerbutalineThe risk or severity of adverse effects can be increased when Labetalol is combined with Terbutaline.
TheophyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Theophylline.
TofacitinibTofacitinib may increase the bradycardic activities of Labetalol.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Labetalol.
TreprostinilTreprostinil may increase the hypotensive activities of Labetalol.
TriprolidineThe risk or severity of adverse effects can be increased when Labetalol is combined with Triprolidine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Labetalol.
VardenafilVardenafil may increase the antihypertensive activities of Labetalol.
VilanterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Vilanterol.
YohimbineYohimbine may decrease the antihypertensive activities of Labetalol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Riva E, Mennini T, Latini R: The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Br J Pharmacol. 1991 Dec;104(4):823-8. [PubMed:1687367 ]
  2. Monopoli A, Bamonte F, Forlani A, Ongini E, Parravicini L: Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment. Arch Int Pharmacodyn Ther. 1984 Dec;272(2):256-63. [PubMed:6151824 ]
  3. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664 ]
  4. Nakagawa Y, Takeda K, Sakurai H, Mitomi A, Imai S: [Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)]. Nihon Yakurigaku Zasshi. 1981 Apr;77(4):435-45. [PubMed:7286847 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. Epub 2009 Oct 17. [PubMed:19879818 ]
  7. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240 ]
  8. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Doggrell SA: The effects of labetalol and dilevalol on isolated cardiovascular preparations of the guinea-pig and rat. J Pharm Pharmacol. 1992 Dec;44(12):1001-6. [PubMed:1361547 ]
  2. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of labetalol, dilevalol, amosulalol and KF-4317 on the rat isolated aorta. J Pharm Pharmacol. 1988 Nov;40(11):812-5. [PubMed:2907566 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664 ]
  5. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. Epub 2009 Oct 17. [PubMed:19879818 ]
  6. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240 ]
  7. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Bernstein JS, Ebert TJ, Stowe DF, Schmeling WT, Nelson MA, Woods MP: Partial attenuation of hemodynamic responses to rapid sequence induction and intubation with labetalol. J Clin Anesth. 1989;1(6):444-51. [PubMed:2696507 ]
  2. Nakamura T, Maruyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Tamsulosin: assessment of affinityof (3)H-P razosin binding to two alpha-1- adrenoceptor subtypes in the canine aorta. Pharmacology. 1999 Nov;59(5):234-8. [PubMed:10529655 ]
  3. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664 ]
  4. Pedersen ME, Cockcroft JR: The vasodilatory beta-blockers. Curr Hypertens Rep. 2007 Aug;9(4):269-77. [PubMed:17686376 ]
  5. Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746 ]
  6. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240 ]
  7. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 05, 2014 12:21